Drug Search Results
More Filters [+]

Atracurium

Alternative Names: atracurium, atracurium besylate, tracrium, tracrium preservative free
Latest Update: 2024-02-06
Latest Update Note: Clinical Trial Update

Product Description

Atracurium is a neuromuscular blocking agent widely used in anesthesia. While the agent is primarily used by anesthesiologists, nurses in the ICU need to know about its mode of action, duration, and adverse effects. The agent is known to cause histamine release, which may be responsible for a variety of side effects. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK499995/)

Mechanisms of Action: ACHE Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Atracurium

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title